<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26401034</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>23</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Single Neutralizing Monoclonal Antibodies Targeting the VP1 GH Loop of Enterovirus 71 Inhibit both Virus Attachment and Internalization during Viral Entry.</ArticleTitle><Pagination><StartPage>12084</StartPage><EndPage>12095</EndPage><MedlinePgn>12084-95</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.02189-15</ELocationID><Abstract><AbstractText Label="UNLABELLED">Antibodies play a critical role in immunity against enterovirus 71 (EV71). However, how EV71-specific antibodies neutralize infections remains poorly understood. Here we report the working mechanism for a group of three monoclonal antibodies (MAbs) that potently neutralize EV71. We found that these three MAbs (termed D5, H7, and C4, respectively) recognize the same conserved neutralizing epitope within the VP1 GH loop of EV71. Single MAbs in this group, exemplified by D5, could inhibit EV71 infection in cell cultures at both the pre- and postattachment stages in a cell type-independent manner. Specifically, MAb treatment resulted in the blockade of multiple steps of EV71 entry, including virus attachment, internalization, and subsequent uncoating and RNA release. Furthermore, we show that the D5 and C4 antibodies can interfere with EV71 binding to its key receptors, including heparan sulfate, SCARB2, and PSGL-1, thus providing a possible explanation for the observed multi-inhibitory function of the MAbs. Collectively, our study unravels the mechanism of neutralization by a unique group of anti-EV71 MAbs targeting the conserved VP1 GH loop. The findings should enhance our understanding of MAb-mediated immunity against enterovirus infections and accelerate the development of MAb-based anti-EV71 therapeutic drugs.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Enterovirus 71 (EV71) is a major causative agent of hand, foot, and mouth disease (HFMD), which has caused significant morbidities and mortalities in young children. Neither a vaccine nor an antiviral drug is available. Neutralizing antibodies are major protective components in EV71 immunity. Here, we unraveled an unusual mechanism of EV71 neutralization by a group of three neutralizing monoclonal antibodies (MAbs). All of these MAbs bound the same conserved epitope located at the VP1 GH loop of EV71. Interestingly, mechanistic studies showed that single antibodies in this MAb group could block EV71 attachment and internalization during the viral entry process and interfere with EV71 binding to heparan sulfate, SCARB2, and PSGL-1 molecules, which are key receptors involved in different steps of EV71 entry. Our findings greatly enhance the understanding of the interplays among EV71, neutralizing antibodies, and host receptors, which in turn should facilitate the development of an MAb-based anti-EV71 therapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015, American Society for Microbiology. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ku</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Xiaohua</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Jinping</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qingwei</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China qwliu@ips.ac.cn huangzhong@ips.ac.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China qwliu@ips.ac.cn huangzhong@ips.ac.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007368" MajorTopicYN="N">Interferometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053585" MajorTopicYN="N">Virus Attachment</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26401034</ArticleId><ArticleId IdType="pmc">PMC4645313</ArticleId><ArticleId IdType="doi">10.1128/JVI.02189-15</ArticleId><ArticleId IdType="pii">JVI.02189-15</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. 2010. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10:778&#x2013;790. doi:10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TC, Guo HR, Su HJ, Yang YC, Chang HL, Chen KT. 2009. Diseases caused by enterovirus 71 infection. Pediatr Infect Dis J 28:904&#x2013;910. doi:10.1097/INF.0b013e3181a41d63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e3181a41d63</ArticleId><ArticleId IdType="pubmed">20118685</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Mao Q, Gao F, Wang J. 2013. Progress on the research and development of human enterovirus 71 (EV71) vaccines. Front Med 7:111&#x2013;121. doi:10.1007/s11684-012-0237-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-012-0237-z</ArticleId><ArticleId IdType="pubmed">23247645</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, Gao F, Wu X, Xu M, Wang JZ. 2013. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccin Immunother 9:1701&#x2013;1705. doi:10.4161/hv.24949.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.24949</ArticleId><ArticleId IdType="pmc">PMC3906269</ArticleId><ArticleId IdType="pubmed">23744508</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Tseng FC, Wang JR, Chi CY, Chong P, Su IJ. 2012. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis 6:e1737. doi:10.1371/journal.pntd.0001737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001737</ArticleId><ArticleId IdType="pmc">PMC3429393</ArticleId><ArticleId IdType="pubmed">22953003</ArticleId></ArticleIdList></Reference><Reference><Citation>Abzug MJ. 2014. The enteroviruses: problems in need of treatments. J Infect 68(Suppl 1):S108&#x2013;S114. doi:10.1016/j.jinf.2013.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2013.09.020</ArticleId><ArticleId IdType="pubmed">24119825</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, Walter TS, Evans G, Axford D, Owen R, Rowlands DJ, Wang J, Stuart DI, Fry EE, Rao Z. 2012. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19:424&#x2013;429. doi:10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. 2012. Crystal structure of human enterovirus 71. Science 336:1274. doi:10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergelson JM, Coyne CB. 2013. Picornavirus entry. Adv Exp Med Biol 790:24&#x2013;41. doi:10.1007/978-1-4614-7651-1_2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4614-7651-1_2</ArticleId><ArticleId IdType="pubmed">23884584</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingler KL, Yoder JL, Carnegie MS, Ashley RE, Makhov AM, Conway JF, Hafenstein S. 2013. The enterovirus 71 A-particle forms a gateway to allow genome release: a cryoEM study of picornavirus uncoating. PLoS Pathog 9:e1003240. doi:10.1371/journal.ppat.1003240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003240</ArticleId><ArticleId IdType="pmc">PMC3605244</ArticleId><ArticleId IdType="pubmed">23555253</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimizu H. 2012. Cellular receptors for human enterovirus species A. Front Microbiol 3:105. doi:10.3389/fmicb.2012.00105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2012.00105</ArticleId><ArticleId IdType="pmc">PMC3313065</ArticleId><ArticleId IdType="pubmed">22470371</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D, Esko JD. 2014. Demystifying heparan sulfate-protein interactions. Annu Rev Biochem 83:129&#x2013;157. doi:10.1146/annurev-biochem-060713-035314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-060713-035314</ArticleId><ArticleId IdType="pmc">PMC7851832</ArticleId><ArticleId IdType="pubmed">24606135</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Poh CL, Sam IC, Chan YF. 2013. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol 87:611&#x2013;620. doi:10.1128/JVI.02226-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02226-12</ArticleId><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="pubmed">23097443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Ohka S, Fujii K, Koike S. 2013. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol 87:3335&#x2013;3347. doi:10.1128/JVI.02070-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02070-12</ArticleId><ArticleId IdType="pmc">PMC3592140</ArticleId><ArticleId IdType="pubmed">23302872</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. 2009. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15:798&#x2013;801. doi:10.1038/nm.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Song Z, Qi Y, Feng X, Xu N, Sun Y, Wu X, Yao X, Mao Q, Li X, Dong W, Wan X, Huang N, Shen X, Liang Z, Li W. 2012. Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. J Biol Chem 287:6406&#x2013;6420. doi:10.1074/jbc.M111.301622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.301622</ArticleId><ArticleId IdType="pmc">PMC3307280</ArticleId><ArticleId IdType="pubmed">22219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskelinen EL, Tanaka Y, Saftig P. 2003. At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol 13:137&#x2013;145. doi:10.1016/S0962-8924(03)00005-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0962-8924(03)00005-9</ArticleId><ArticleId IdType="pubmed">12628346</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang M, Wang X, Wang Q, Wang Y, Lin J, Sun Y, Li X, Zhang L, Lou Z, Wang J, Rao Z. 2014. Molecular mechanism of SCARB2-mediated attachment and uncoating of EV71. Protein Cell 5:692&#x2013;703. doi:10.1007/s13238-014-0087-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-014-0087-3</ArticleId><ArticleId IdType="pmc">PMC4145081</ArticleId><ArticleId IdType="pubmed">24986489</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Lee H, Hafenstein S, Kataoka C, Wakita T, Bergelson JM, Shimizu H. 2013. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. PLoS Pathog 9:e1003511. doi:10.1371/journal.ppat.1003511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003511</ArticleId><ArticleId IdType="pmc">PMC3723564</ArticleId><ArticleId IdType="pubmed">23935488</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. 2009. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 15:794&#x2013;797. doi:10.1038/nm.1961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X, Ku Z, Liu Q, Wang X, Shi J, Zhang Y, Kong L, Cong Y, Huang Z. 2014. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J Virol 88:72&#x2013;81. doi:10.1128/JVI.01848-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01848-13</ArticleId><ArticleId IdType="pmc">PMC3911748</ArticleId><ArticleId IdType="pubmed">24131712</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. 2001. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20:895&#x2013;904. doi:10.1016/S0264-410X(01)00385-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, Yan JJ, Su IJ. 2000. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 7:523&#x2013;528. doi:10.1007/BF02253368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02253368</ArticleId><ArticleId IdType="pubmed">11060501</ArticleId></ArticleIdList></Reference><Reference><Citation>Both L, Banyard AC, van Dolleweerd C, Wright E, Ma JK, Fooks AR. 2013. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine 31:1553&#x2013;1559. doi:10.1016/j.vaccine.2013.01.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.01.025</ArticleId><ArticleId IdType="pmc">PMC7115371</ArticleId><ArticleId IdType="pubmed">23370150</ArticleId></ArticleIdList></Reference><Reference><Citation>Marasco WA, Sui J. 2007. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 25:1421&#x2013;1434. doi:10.1038/nbt1363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1363</ArticleId><ArticleId IdType="pmc">PMC7097443</ArticleId><ArticleId IdType="pubmed">18066039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim XF, Jia Q, Khong WX, Yan B, Premanand B, Alonso S, Chow VT, Kwang J. 2012. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS One 7:e29751. doi:10.1371/journal.pone.0029751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0029751</ArticleId><ArticleId IdType="pmc">PMC3261156</ArticleId><ArticleId IdType="pubmed">22279543</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang GH, Luo YJ, Wu XY, Si BY, Lin L, Zhu QY. 2010. Monoclonal antibody induced with inactivated EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection. Virol J 7:106. doi:10.1186/1743-422X-7-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-106</ArticleId><ArticleId IdType="pmc">PMC2887433</ArticleId><ArticleId IdType="pubmed">20500892</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Xu L, He D, Yang L, Liu C, Chen Y, Shih JW, Zhang J, Zhao Q, Cheng T, Xia N. 2014. In vivo time-related evaluation of a therapeutic neutralization monoclonal antibody against lethal enterovirus 71 infection in a mouse model. PLoS One 9:e109391. doi:10.1371/journal.pone.0109391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0109391</ArticleId><ArticleId IdType="pmc">PMC4184856</ArticleId><ArticleId IdType="pubmed">25279734</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Lim PY, Perera R, Cardosa J, Suksatu A, Kuhn RJ, Rossmann MG. 2014. Neutralizing antibodies can initiate genome release from human enterovirus 71. Proc Natl Acad Sci U S A 111:2134&#x2013;2139. doi:10.1073/pnas.1320624111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1320624111</ArticleId><ArticleId IdType="pmc">PMC3926013</ArticleId><ArticleId IdType="pubmed">24469789</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Shi J, Liu Q, Huang Z. 2012. Development of murine monoclonal antibodies with potent neutralization effects on enterovirus 71. J Virol Methods 186:193&#x2013;197. doi:10.1016/j.jviromet.2012.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.06.025</ArticleId><ArticleId IdType="pubmed">22771741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Ku Z, Liu Q, Wang X, Chen T, Ye X, Li D, Jin X, Huang Z. 2015. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine 33:2335&#x2013;2341. doi:10.1016/j.vaccine.2015.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.03.034</ArticleId><ArticleId IdType="pubmed">25820068</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Ye X, Huang X, Cai Y, Liu Q, Li Y, Su Z, Huang Z. 2013. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One 8:e57601. doi:10.1371/journal.pone.0057601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057601</ArticleId><ArticleId IdType="pmc">PMC3579802</ArticleId><ArticleId IdType="pubmed">23451250</ArticleId></ArticleIdList></Reference><Reference><Citation>Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH. 2005. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437:764&#x2013;769. doi:10.1038/nature03956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03956</ArticleId><ArticleId IdType="pmc">PMC7095628</ArticleId><ArticleId IdType="pubmed">16193056</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson BS, Moesker B, Smit JM, Wilschut J, Diamond MS, Fremont DH. 2009. A therapeutic antibody against West Nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog 5:e1000453. doi:10.1371/journal.ppat.1000453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000453</ArticleId><ArticleId IdType="pmc">PMC2679195</ArticleId><ArticleId IdType="pubmed">19478866</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin SK, Dowd KA, Shrestha B, Nelson CA, Edeling MA, Johnson S, Pierson TC, Diamond MS, Fremont DH. 2012. Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog 8:e1002930. doi:10.1371/journal.ppat.1002930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002930</ArticleId><ArticleId IdType="pmc">PMC3464233</ArticleId><ArticleId IdType="pubmed">23055922</ArticleId></ArticleIdList></Reference><Reference><Citation>Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT, Yip A, Schul W, Aung M, Kostyuchenko VA, Leo YS, Chan SH, Smith KG, Chan AH, Zou G, Ooi EE, Kemeny DM, Tan GK, Ng JK, Ng ML, Alonso S, Fisher D, Shi PY, Hanson BJ, Lok SM, MacAry PA. 2012. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 4:139ra183. doi:10.1126/scitranslmed.3003888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003888</ArticleId><ArticleId IdType="pubmed">22723463</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian M, Hu H, Zuo T, Wang G, Zhang L, Zhou P. 2013. Unraveling of a neutralization mechanism by two human antibodies against conserved epitopes in the globular head of H5 hemagglutinin. J Virol 87:3571&#x2013;3577. doi:10.1128/JVI.01292-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01292-12</ArticleId><ArticleId IdType="pmc">PMC3592130</ArticleId><ArticleId IdType="pubmed">23269809</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogle JM. 2002. Poliovirus cell entry: common structural themes in viral cell entry pathways. Annu Rev Microbiol 56:677&#x2013;702. doi:10.1146/annurev.micro.56.012302.160757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.56.012302.160757</ArticleId><ArticleId IdType="pmc">PMC1500891</ArticleId><ArticleId IdType="pubmed">12142481</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuthill TJ, Groppelli E, Hogle JM, Rowlands DJ. 2010. Picornaviruses. Curr Top Microbiol Immunol 343:43&#x2013;89. doi:10.1007/82_2010_37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/82_2010_37</ArticleId><ArticleId IdType="pmc">PMC3018333</ArticleId><ArticleId IdType="pubmed">20397067</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, Chou AH, Wang YC, Chen YC, Yang CS, Chong PC. 2011. Purification and characterization of enterovirus 71 viral particles produced from Vero cells grown in a serum-free microcarrier bioreactor system. PLoS One 6:e20005. doi:10.1371/journal.pone.0020005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020005</ArticleId><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrov DS. 2004. Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol 2:109&#x2013;122. doi:10.1038/nrmicro817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro817</ArticleId><ArticleId IdType="pmc">PMC7097642</ArticleId><ArticleId IdType="pubmed">15043007</ArticleId></ArticleIdList></Reference><Reference><Citation>Klasse PJ, Sattentau QJ. 2002. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 83:2091&#x2013;2108. doi:10.1099/0022-1317-83-9-2091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-83-9-2091</ArticleId><ArticleId IdType="pubmed">12185262</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton DR, Saphire EO, Parren PW. 2001. A model for neutralization of viruses based on antibody coating of the virion surface. Curr Top Microbiol Immunol 260:109&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">11443871</ArticleId></ArticleIdList></Reference><Reference><Citation>Reading SA, Dimmock NJ. 2007. Neutralization of animal virus infectivity by antibody. Arch Virol 152:1047&#x2013;1059. doi:10.1007/s00705-006-0923-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-006-0923-8</ArticleId><ArticleId IdType="pubmed">17516034</ArticleId></ArticleIdList></Reference><Reference><Citation>Lineberger DW, Graham DJ, Tomassini JE, Colonno RJ. 1990. Antibodies that block rhinovirus attachment map to domain 1 of the major group receptor. J Virol 64:2582&#x2013;2587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC249435</ArticleId><ArticleId IdType="pubmed">1970837</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Fischer ER, Kouiavskaia D, Hansen BT, Ludtke SJ, Bidzhieva B, Makiya M, Agulto L, Purcell RH, Chumakov K. 2013. Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor. Proc Natl Acad Sci U S A 110:20242&#x2013;20247. doi:10.1073/pnas.1320041110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1320041110</ArticleId><ArticleId IdType="pmc">PMC3864303</ArticleId><ArticleId IdType="pubmed">24277851</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Yafal AG, Lee YM, Hogle J, Chow M. 1994. Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature. J Virol 68:3965&#x2013;3970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC236902</ArticleId><ArticleId IdType="pubmed">7514682</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Clavero MA, Escribano-Romero E, Douglas AJ, Ley V. 2001. The N-terminal region of the VP1 protein of swine vesicular disease virus contains a neutralization site that arises upon cell attachment and is involved in viral entry. J Virol 75:1044&#x2013;1047. doi:10.1128/JVI.75.2.1044-1047.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.2.1044-1047.2001</ArticleId><ArticleId IdType="pmc">PMC114001</ArticleId><ArticleId IdType="pubmed">11134318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim XF, Jia Q, Chow VT, Kwang J. 2013. Characterization of a novel monoclonal antibody reactive against the N-terminal region of enterovirus 71 VP1 capsid protein. J Virol Methods 188:76&#x2013;82. doi:10.1016/j.jviromet.2012.11.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.11.038</ArticleId><ArticleId IdType="pubmed">23219932</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain KM, Leong KL, Ng MM, Chu JJ. 2011. The essential role of clathrin-mediated endocytosis in the infectious entry of human enterovirus 71. J Biol Chem 286:309&#x2013;321. doi:10.1074/jbc.M110.168468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.168468</ArticleId><ArticleId IdType="pmc">PMC3012988</ArticleId><ArticleId IdType="pubmed">20956521</ArticleId></ArticleIdList></Reference><Reference><Citation>McLeish NJ, Williams CH, Kaloudas D, Roivainen MM, Stanway G. 2012. Symmetry-related clustering of positive charges is a common mechanism for heparan sulfate binding in enteroviruses. J Virol 86:11163&#x2013;11170. doi:10.1128/JVI.00640-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00640-12</ArticleId><ArticleId IdType="pmc">PMC3457184</ArticleId><ArticleId IdType="pubmed">22855495</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlasak M, Goesler I, Blaas D. 2005. Human rhinovirus type 89 variants use heparan sulfate proteoglycan for cell attachment. J Virol 79:5963&#x2013;5970. doi:10.1128/JVI.79.10.5963-5970.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.10.5963-5970.2005</ArticleId><ArticleId IdType="pmc">PMC1091682</ArticleId><ArticleId IdType="pubmed">15857982</ArticleId></ArticleIdList></Reference><Reference><Citation>Zautner AE, Korner U, Henke A, Badorff C, Schmidtke M. 2003. Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection. J Virol 77:10071&#x2013;10077. doi:10.1128/JVI.77.18.10071-10077.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.18.10071-10077.2003</ArticleId><ArticleId IdType="pmc">PMC224569</ArticleId><ArticleId IdType="pubmed">12941917</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamura K, Nishimura Y, Abo M, Wakita T, Shimizu H. 2011. Adaptive mutations in the genomes of enterovirus 71 strains following infection of mouse cells expressing human P-selectin glycoprotein ligand-1. J Gen Virol 92:287&#x2013;291. doi:10.1099/vir.0.022418-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.022418-0</ArticleId><ArticleId IdType="pmc">PMC3081077</ArticleId><ArticleId IdType="pubmed">20943886</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>